StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD)

StockNews.com initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note released on Tuesday. The brokerage issued a hold rating on the stock.

TherapeuticsMD Price Performance

TherapeuticsMD stock opened at $1.96 on Tuesday. TherapeuticsMD has a fifty-two week low of $1.84 and a fifty-two week high of $4.73. The stock’s 50 day simple moving average is $2.17 and its two-hundred day simple moving average is $2.27.

Hedge Funds Weigh In On TherapeuticsMD

An institutional investor recently bought a new position in TherapeuticsMD stock. ADAR1 Capital Management LLC acquired a new stake in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 272,160 shares of the company’s stock, valued at approximately $612,000. ADAR1 Capital Management LLC owned about 2.57% of TherapeuticsMD at the end of the most recent quarter. Hedge funds and other institutional investors own 30.74% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.